Trial Profile
A Multicenter, Open-label, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Rozanolixizumab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Proof of concept
- Sponsors UCB
- 08 Sep 2020 According to an UCB media release, results from this study were published in the September online issue of Blood Advances.
- 08 Sep 2020 Results published in the UCB Media Release
- 10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology